CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

This phase II trial tests how well CPI-613 (devimistat) in combination with hydroxychloroquine (HCQ) and 5-fluorouracil (5-FU) or gemcitabine works in patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that have not responded to chemotherapy medications (chemorefractory). Metabolism is how the cells in the body use molecules (carbohydrates, fats, and proteins) from food to get the energy they need to grow, reproduce and stay healthy. Tumor cells, however, do this process differently as they use

Trial Details

NCT ID

NCT05733000

Phase

PHASE2

Sponsor

Northwestern University

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Biospecimen Collection
Computed Tomography
Devimistat
Fluorouracil
Gemcitabine Hydrochloride
Hydroxychloroquine

Locations (sample)

Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

Patients must have histologically confirmed cancer for which standard-of-care curative measures are no longer effective or be intolerant to those a…
Gastroesophageal
Urothelial
Non-small cell lung (adenocarcinoma only)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →